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Abstract 1 
Patients regularly taking non-steroidal anti-inflammatory drugs (NSAIDs) such as 2 
indomethacin (IND) run the risk of small intestinal injuries. In this study, we have 3 
developed an oral nanotherapeutic by using a redox nanoparticle (RNPO), which is 4 
prepared by self-assembly of an amphiphilic block copolymer that possesses nitroxide 5 
radicals as side chains of hydrophobic segment via ether linkage, to reduce 6 
inflammation in mice with IND-induced small intestinal injury. The localization and 7 
accumulation of RNPO in the small intestine were determined using fluorescent-labeled 8 
RNPO and electron spin resonance. After oral administration, the values of area under 9 
the concentration-time curve of RNPO in both the jejunum and ileum tissues were about 10 
40 times higher than those of low-molecular-weight nitroxide radical compounds. By 11 
this specific accumulation of RNPO in small intestine, RNPO remarkably suppressed 12 
inflammatory mediators such as myeloperoxidase, superoxide anion, and 13 
malondialdehyde in the small intestines of IND-treated mice. Compared to 14 
low-molecular-weight nitroxide radical compounds, RNPO also significantly increased 15 
the survival rate of mice treated daily with IND. On the basis of these results, RNPO is 16 
promising as a nanotherapeutic for treatment of inflammation in the small intestine of 17 
patients receiving NSAIDs.  18 
4 
 
1. Introduction 1 
Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and 2 
indomethacin (IND) are the most commonly prescribed drugs for their antipyretic, 3 
analgesic, and anti-inflammatory effects. The total consumption of NSAIDs is 4 
increasing in accordance with the increase in the incidence of orthopedic and 5 
cardiovascular diseases [1-3]. However, it has been reported that the use of NSAIDs 6 
causes severe adverse effects including ulcers, erosions, bleeding, perforation, and 7 
strictures in the gastrointestinal (GI) tract such as stomach and small intestine [4-9]. The 8 
absolute number of patients with serious NSAIDs-induced GI complications is 9 
increasing due to the expansion of long-term NSAIDs treatment. Though the etiology 10 
and pathogenesis of NSAIDs-induced inflammation are not well understood [10], 11 
several studies have reported that overproduction of reactive oxygen species (ROS) and 12 
an imbalance of important antioxidants exist in the intestine of patients receiving 13 
repeated doses of NSAIDs, leading to oxidative damage [8, 11-14]. Self-sustaining 14 
cycles of oxidant production may amplify inflammation and mucosal injury. Thus far, it 15 
has been reported that antioxidant compounds and free radical scavengers heal 16 
NSAIDs-induced inflammation [15, 16]. However, orally administered 17 
low-molecular-weight (LMW) compounds are not sufficiently effective due to their 18 
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non-specific distribution to the entire body, metabolism in the GI tract, low retention in 1 
the lesion area, and undesired adverse effects. 2 
To address these issues, we have developed a newly designed oral 3 
nanotherapeutic using redox nanoparticles (RNPO) with ROS scavenging potential of 4 
nitroxide radicals for treatment of inflammation in the GI tract. RNPO is a 5 
core-shell-type polymeric micelle with approximately 40 nm in diameter, prepared by 6 
the self-assembly of methoxy-poly(ethylene 7 
glycol)-b-poly[4-(2,2,6,6-tetramethylpiperidine-1-oxyl)oxymethylstyrene] 8 
(MeO-PEG-b-PMOT), which is an amphiphilic block copolymer possessing nitroxide 9 
radicals as side chains of hydrophobic segment via ether linkages (Figure 1a). Thus far, 10 
we have found that orally administered RNPO specifically accumulates in the colonic 11 
mucosa and effectively suppresses inflammation in mice with colitis [17]. In addition, 12 
we have previously confirmed that, as RNPO is not absorbed into the bloodstream via 13 
the mesentery, it does not cause the adverse effects of nitroxide radicals in the entire 14 
body [17]. 15 
The objective of this work was to confirm the protective effect of RNPO on 16 
NSAIDs-induced small intestinal inflammation in mice. The accumulation tendency of 17 
orally administered RNPO and the suppression of ROS and inflammation in the small 18 
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intestine by RNPO were investigated in detail (Figure 1b). 1 
 2 
2. Materials and methods 3 
2.1. Preparation of RNPO 4 
RNPO was prepared by the self-assembly of an amphiphilic block copolymer 5 
(MeO-PEG-b-PMOT) composed of the hydrophilic PEG segment and the hydrophobic 6 
poly(4-methylstyrene) segment possessing nitroxide radicals as side chains via ether 7 
linkages, according to our previous study [18]. Briefly, poly(ethylene 8 
glycol)-b-poly(chloromethylstyrene) (MeO-PEG-b-PCMS) was synthesized by the 9 
radical telomerization of chloromethylstyrene using MeO-PEG-SH (Mn = 5000; NOF 10 
corporation, Tokyo, Japan) as a telogen. The chloromethyl groups were converted to 11 
2,2,6,6-tetramethylpiperidinyl-1-oxyls (TEMPOs) via a Williamson ether synthesis of 12 
benzyl chloride in the MeO-PEG-b-PCMS block copolymer with the alkoxide of 13 
4-hydroxyl-2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL). To prepare RNPO, the 14 
MeO-PEG-b-PMOT was dissolved in N,N-dimethylformamide (Wako Pure Chemicals, 15 
Osaka, Japan), and transferred into a membrane tube (SpectraPor, molecular weight 16 
cut-off size: 3,500 Da, Spectrum Laboratories Inc., Savannah, GA, USA) and then 17 
dialyzed for 24 h against 2 L of distilled water, which was changed after 2, 4, 8, 12, and 18 
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20 h. After dialysis, the diameter of the obtained particles was determined using 1 
dynamic light scattering measurements (Zetasizer Nanoseries ZEN3600, Malvern 2 
Instruments Ltd., Worcestershire, UK). 3 
 4 
2.2. Animal preparation 5 
All experiments were carried out using 6-week-old male ICR mice 6 
(approximately 30 g) purchased from Charles River Japan, Inc. (Yokohama, Japan). 7 
Mice were maintained in the experimental animal facilities at the University of Tsukuba. 8 
All experiments were performed according to the Guide for the Care and Use of 9 
Laboratory Animals Resource Center of the University of Tsukuba. 10 
 11 
2.3. Localization of RNPO in the small intestine 12 
The localization of RNPO in the small intestine was determined by fluorescent 13 
rhodamine-labeled RNPO. Rhodamine-labeled RNPO was prepared via a thiourethane 14 
bond between MeO-PEG-b-PMOT possessing reduced TEMPO moieties and 15 
rhodamine B isothiocyanate in the presence of sodium hydride. One milliliter of 16 
rhodamine-labeled RNPO (5 mg/mL) was orally administered to mice, and the mice 17 
were sacrificed at 0.5, 1, 4, and 12 h after oral administration. Residues in the ileum 18 
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were gently removed with phosphate buffer (pH 7.4), and 7-µm–thick sections of ileum 1 
were prepared. Localization of rhodamine-labeled RNPO was recorded using a 2 
fluorescent microscope (FL-III; Leica, Tokyo, Japan).  3 
 4 
2.4. Biodistribution of RNPO 5 
One milliliter of RNPO (13.34 mg/mL) or LMW TEMPOL (2.49 mg/mL) was 6 
orally administered to mice, and the mice were sacrificed at 0.25, 0.5, 1, 4, and 12 h 7 
after oral administration. It should be noted that the concentrations of nitroxide radicals 8 
in RNPO and TEMPOL were equivalent, and were adjusted by measurements of 9 
electron spin resonance (ESR) spectra. The jejunum, ileum, and blood were isolated 10 
after operation. The jejunum and ileum tissues were gently washed with 0.9% normal 11 
saline to remove any residual food. About 1 g jejunum or 0.5 g ileum tissues were 12 
homogenized in 0.5 mL of phosphate buffer (pH 7.4) containing potassium ferricyanide 13 
(200 mM) on ice. The ESR signal intensities in homogenized samples were analyzed 14 
using an X-band ESR spectrometer (JES-TE25X; JEOL, Tokyo, Japan) at room 15 
temperature under the following conditions: frequency, 9.41 GHz; power, 10.00 mW; 16 
center field, 333.3; sweep width, 5 mT; sweep time, 0.5 min; modulation, 0.1 mT; time 17 
constant, 0.1 s. 18 
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The accumulation of RNPO in the mucosa and muscle layers of jejunum and 1 
ileum was also determined by the ESR assay. To separate the mucosa and muscle of 2 
both jejunum and ileum, the methods of Rang et al. [19] and Patonet et al. [20] were 3 
employed. Briefly, 1 mL of RNPO (13.34 mg/mL) or LMW TEMPOL (2.49 mg/mL) 4 
was orally administered to mice, and the mice were sacrificed at 0.5 h after 5 
administration. The intestinal content was gently flushed with 0.9% normal saline. Then, 6 
the jejunum and ileum were longitudinally opened and the mucosa was scraped with a 7 
blunt spatula. 8 
 9 
2.5. Experimental design using IND-induced small intestine inflammation model in mice 10 
Small intestine inflammation in mice was induced by the oral administration of 11 
IND (10 mg/kg body weight [BW]; Wako Pure Chemicals), which was suspended in 12 
distilled water with 1% carboxymethylcellulose (CMC; Wako Pure Chemicals) and use 13 
immediately. All mice were fasted for 24 h before the experiment and divided into the 14 
following 4 groups of 5 animals each. 15 
Group I (Control): mice were received with distilled water 1 h before the oral 16 
administration of CMC solution (1% w/v). 17 
Group II (IND): mice were received with distilled water 1 h before the oral 18 
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administration of IND. 1 
Group III (IND + TEMPOL): mice were treated with TEMPOL (18.67 mg/kg 2 
BW) 1 h before the oral administration of IND. 3 
Group IV (IND + RNPO): mice were treated with RNPO (100 mg/kg BW with 4 
same amount of TEMPOL in RNPO) 1 h before the oral administration of IND. 5 
The animals were given ad libitum access to food and water after the 6 
administration of IND. Twelve hours after the administration of IND or CMC, the 7 
animals were sacrificed by cervical dislocation and the small intestine tissues were kept 8 
on ice. The intestine was gently washed with 0.9% normal saline to remove any residual 9 
food. The whole small intestine was separated into the duodenum, jejunum, and ileum. 10 
Five-centimeter lengths of the jejunum and ileum were isolated for hematoxylin and 11 
eosin (H&E) staining. The remaining tissues were used for measurements of 12 
myeloperoxidase (MPO) activity, superoxide anion production, and malondialdehyde 13 
(MDA) level. 14 
 15 
2.6. H&E staining 16 
Jejunum and ileum segments of mice were opened along the antimesenteric 17 
border, gently rinsed to remove fecal contents, fixed on a 4% (v/v) buffered formalin 18 
11 
 
solution and embedded in paraffin for use in histopathological examination. 1 
Seven-micrometer-thick sections were cut, deparaffinized, hydrated and stained with 2 
H&E. The histology of the small intestine was evaluated using a microscope (DM 3 
RXA2; Leica, Tokyo, Japan).  4 
 5 
2.7. Measurement of MPO activity 6 
MPO activity was measured according to the method of Bradley et al. [21]. 7 
Samples of intestinal tissue from treated mice were excised and homogenized in cold 50 8 
mM phosphate buffer (pH 6.0) containing 0.5% (w/v) hexadecyltrimethylammonium 9 
bromide. Supernatants were collected by centrifugation for 10 min at 10,000 rpm at 4°C 10 
and kept at -80°C until use. The enzymatic reaction was carried out in a 96-well plate by 11 
adding 190 µL of 50 mM phosphate buffer (pH 6), 5 µL of 0.5% (w/v) o-dianisidine 12 
hydrochloride, 10 µL of the supernatant sample, and 5 µL of 20 mM H2O2. After 13 
allowing the reaction to proceed for 30 min at room temperature, the absorbance at 460 14 
nm was measured using a plate reader (Varioskan Flash; Thermo Scientific, Tokyo, 15 
Japan). MPO activity was determined by comparison to a standard MPO curve (Sigma 16 
Chemical Co., St. Louis, MO, USA). The protein concentration of the supernatant 17 
sample was measured using a BCA kit (Thermo Scientific Pierce Protein Research 18 
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Products, Rockford, IL, USA). Values are expressed as MPO units/µg protein. 1 
 2 
2.8. Measurement of production of superoxide anion 3 
Superoxide anion generation was determined by the nitro blue tetrazolium (NBT) 4 
assay [22]. Samples of intestinal tissue from treated mice were collected, homogenized 5 
in cold 10 mM phosphate buffer (pH 7.4), and centrifuged at 10,000 rpm at 4°C for 15 6 
min to obtain the supernatant. The reaction was carried out in a 96-well plate by adding 7 
the supernatant sample, 10 mM boric acid-sodium hydroxide buffer, and the enzymatic 8 
reaction mixture consisting of 10 mM phosphate buffer (pH 7.4) containing 0.1 mM 9 
xanthine, 0.1 mM ethylene diaminetetraacetic acid, 0.1 mM NBT, and 0.1 unit xanthine 10 
oxidase in a final volume of 1 mL. After 10 min at room temperature, the absorbance at 11 
560 nm was measured using a plate reader. The amount of superoxide anion was 12 
calculated per wet tissue weight. 13 
 14 
2.9. Measurement of lipid peroxidation 15 
Lipid peroxidation was evaluated by measuring the amount of MDA, following 16 
the method of Ohkawa et al. [23]. Samples of intestinal tissue from treated mice were 17 
collected, homogenized in cold 0.1 mM phosphate buffer (pH 7.4), and centrifuged at 18 
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10,000 rpm at 4°C for 15 min. An aliquot of the supernatant was added to the reaction 1 
mixture containing 8% (w/v) sodium dodecyl sulfate, 20% (v/v) acetic acid, 0.8% (w/v) 2 
thiobarbituric acid, and distilled water. After incubation at 95°C for 1 h, the amount of 3 
MDA formed in the reaction mixture was measured using a plate reader at an 4 
absorbance of 532 nm. 1,1,3,3-tetramethoxypropane was used as the standard. The 5 
protein concentration of the supernatant sample was measured using the BCA kit as 6 
well as the MPO assay. 7 
 8 
2.10. Survival rate experiment 9 
The survival rate of mice was determined by orally administering IND (10 mg/kg 10 
BW) daily for 7 d. LMW TEMPOL (18.67 mg/kg BW) and RNPO (100 mg/kg BW) 11 
were also orally administered daily at 1 h before IND administration until 7 d, and the 12 
number of surviving mice was counted for 7 d. 13 
 14 
2.12. Statistical analysis 15 
All data are expressed as mean ± SEM. from 5 mice per group. Statistical analysis 16 
using SPSS (IBM Corp., NY, USA) was performed using one-way analysis of variance, 17 
followed by Tukey’s post-hoc test. A P-value of less than 0.05 was considered 18 
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significant for all statistical analyses. 1 
 2 
3. Results and Discussion 3 
3.1. The specific accumulation of RNPO in small intestine 4 
The accumulation of nanoparticles in the small intestine is one of the most 5 
important features for an effective nanotherapeutic against small intestinal injury. We 6 
have previously confirmed that a fairly large amount of RNPO (ca. 15% of injected dose) 7 
accumulated in the colonic mucosa by oral administration. In order to confirm the effect 8 
of RNPO on NSAID-induced injury, we examined the localization of RNPO in the small 9 
intestine using fluorescent rhodamine-labeled RNPO. When LMW rhodamine was 10 
administered orally, almost no fluorescent signal was observed at 1 h (Figure 2a). On 11 
the contrary, a strong fluorescent signal of RNPO in the mucosa area of ileum was 12 
observed (Figures 2b–f). In addition, the fluorescent signal was observed until 12 h after 13 
oral administration of rhodamine-labeled RNPO, indicating that the effective 14 
accumulation of RNPO in the small intestinal area continued for at least half a day. 15 
To obtain quantitative information on the tendency of RNPO to accumulate in the 16 
small intestinal areas, ESR analysis was carried out in comparison with LMW 17 
TEMPOL. At 0.5 h after administration of LMW TEMPOL to mice, 4.2 and 1.4% of 18 
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the initial dose was observed in the jejunum and ileum areas, respectively. At 1 h after 1 
administration, however, almost no ESR signal was observed, as shown in Figures 3a 2 
and b. In contrast, when RNPO was orally administrated to mice, a considerably higher 3 
accumulation of RNPO in the small intestine was observed. The values of area under the 4 
concentration-time curve (AUC), an important parameter in biopharmaceuticals and 5 
pharmacokinetics, of RNPO were 3.3 and 2.1 mg·h/mL in the jejunum and ileum areas, 6 
respectively, which were significantly higher than those of LMW TEMPOL (0.09 and 7 
0.05 mg·h/mL) (Table 1).  8 
The morphology of RNPO in the small intestine was determined by ESR spectra. 9 
At 0.5 h after oral administration, the ESR signals of LMW TEMPOL in the ileum 10 
showed a sharp triplet due to an interaction between the 14N nuclei and the unpaired 11 
electron (Figure 3c). In contrast, the ESR signals of RNPO even in the ileum were 12 
consistently broad (Figure 3d), and this signal was observed until 4 h after oral 13 
administration, indicating that the TEMPO radicals are still located in the solid core of 14 
the polymeric micelles for a long time, even in the terminal portion of small intestine. 15 
This might be one of the reasons preventing its uptake into blood via the mesentery. 16 
The distribution of RNPO in the small intestine region was further investigated in 17 
detail. For this objective, the mucosa and muscle of both jejunum and ileum were 18 
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separated, and RNPO localization was investigated by ESR measurement. As shown in 1 
Table 2, at 0.5 h after oral administration, the amounts of RNPO in the jejunum mucosa, 2 
jejunum muscle, ileum mucosa, and ileum muscle were 30.6, 7.4, 15.3, and 4.1% of the 3 
initial dose, respectively. The amounts of RNPO in the mucosa layer were about 4 times 4 
higher than those in the muscle layer in both jejunum and ileum. These results confirm 5 
that our nanoparticle specifically accumulated in the intestinal mucosa preferentially. 6 
Lamprecht et al. reported that the size determines the accumulation of polystyrene 7 
nanoparticles in the intestinal mucosal layer [24]. However, in the harsh environment of 8 
the GI tract, which includes gastric juices with strong acid, digestive enzymes, and bile 9 
acid, these polystyrene nanoparticles do not always stably maintain their sizes. Block 10 
copolymers can self-assemble to form a polymeric micelle structure with a dense PEG 11 
brush on the surface [25]. The optimal structure allows RNPO to easily diffuse in the 12 
mucosa and inflammatory areas in GI tract. Because RNPO did not disintegrate even in 13 
the intestinal mucosa, its nanosize of 40 nm prevented the uptake of RNPO into the 14 
bloodstream [17], suggesting a lack of systemic adverse effects, such as hypertension 15 
[26]. Furthermore, the covalent conjugation of nitroxide radicals to the backbone of 16 
polymeric micelles is another important strategy to suppress the toxicity of nitroxide 17 
radicals and deliver them to a target area in vivo without drug leakage. Based on these 18 
17 
 
reasons, RNPO is the ideal material for accumulation in the small intestine.  1 
 2 
3.2. The protective effect of RNPO on IND-induced small intestinal inflammation 3 
Since it has been confirmed that orally administered RNPO significantly 4 
accumulated in the intestinal area, the ROS scavenging efficiency of RNPO in 5 
IND-induced small intestinal inflammation was examined. We have previously 6 
confirmed that non-disintegrated RNPO has a definite ROS scavenging ability in vitro 7 
[18]. Here, the protective effects of RNPO on IND-induced inflammation in mice were 8 
investigated. In this experiment, the encapsulation of IND into the hydrophobic core of 9 
RNPO in GI tract is ignorable, because almost IND exists outside of RNPO in GI tract, 10 
which is based on the maximum IND encapsulation capacity in the hydrophobic core of 11 
RNPO (6.7 wt%) (see Supporting information). After the treatments shown in the 12 
experimental section, histological assessments were performed in both the jejunum and 13 
ileum areas. As shown in Figures 4b and f, gross damage, such as focal and upper 14 
villous necrosis, was observed in both the jejunum and ileum of mice treated with IND, 15 
compared to those of control mice (Figures 4a and e). When LMW TEMPOL was orally 16 
administered prior to IND-treated mice, the jejunum area was almost similar to that of 17 
control mice (Figure 4c); however, a part of a necrotic villus was observed in the ileum 18 
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(see arrow in Figure 4g). Since LMW TEMPOL is absorbed from the upper GI tract, 1 
most of it might not reach to the ileum area. On the contrary, the histology of the small 2 
intestine from RNPO-treated mice showed almost no damage and was similar to that 3 
from control mice in both the jejunum and ileum areas (Figures 4d and h). 4 
The different efficiencies of pretreatment with TEMPOL and RNPO on 5 
IND-treated mice were further investigated by measuring the levels of inflammatory 6 
mediators, such as MPO, superoxide anion, and MDA, which indicate the extent of 7 
neutrophil invasion, oxidative stress, and lipid oxidation, respectively. As shown in 8 
Figure 5a, MPO activity significantly increased in small intestine of IND-treated mice, 9 
especially in ileum tissues, compared to those of control mice, indicating the increase in 10 
neutrophil invasion especially in the ileum region. When LMW TEMPOL was orally 11 
administered to IND-treated mice, the MPO level decreased effectively, both in jejunum 12 
and in ileum (Figure 5a). However, it was not suppressed to the controlled level in the 13 
ileum, indicating that LMW TEMPOL could not suppress neutrophil invasion 14 
completely. On the contrary, the level of MPO decreased significantly and was almost 15 
the same level as that of control both in jejunum and in ileum of mice pretreated with 16 
RNPO, indicating that RNPO could suppress neutrophil invasion almost completely both 17 
in jejunum and in ileum regions. As shown in Figure 5b, the superoxide level increased 18 
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significantly by IND-treatment both in jejunum and in ileum. Since the MPO level in 1 
the jejunum did not increase to the level in the ileum, the higher superoxide level in the 2 
jejunum might be due to the direct toxicity of IND in addition to neutrophil invasion. 3 
When LMW TEMPOL was administered to the IND-treated mice, the production of 4 
superoxide anion decreased in the jejunum area but not in the ileum (Figure 5b), 5 
suggesting that the most of LMW TEMPOL might not reach to the ileum area, 6 
consistent with the result of H&E staining, as can be seen in Figures 4c and g. When 7 
RNPO was used, the amount of superoxide anion both in the jejunum and in ileum was 8 
significantly suppressed, compared to that of IND-treated mice (Figure 5b), indicating 9 
that RNPO effectively scavenged overproduced superoxide anion in IND-treated mice. 10 
We also confirmed lipid oxidation by measuring the amount of MDA. As shown in 11 
Figure 5c, higher amounts of oxidative products were observed in both the jejunum and 12 
ileum by IND treatment. LMW TEMPOL did not decrease the amounts of these 13 
oxidative compounds well, especially in the jejunum area. On the other hand, all 14 
oxidative stress markers both in jejunum and in ileum tissues of mice pretreated with 15 
RNPO were significantly decreased compared to those of mice treated with IND only. 16 
Importantly, these oxidative stress markers both in jejunum and in ileum tissues of mice 17 
pretreated with RNPO also showed the statistically significant differences from those 18 
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pretreated with LMW TEMPOL. Taken together, these results clearly indicate that 1 
pretreatment with RNPO effectively prevented IND-induced inflammation by ROS 2 
scavenging, unlike LMW TEMPOL. 3 
Finally, we confirmed the consequences of pretreatment with TEMPOL and 4 
RNPO in IND-treated mice by a survival experiment. It is noted that mortality was 5 
induced by daily administration of IND to mice for 7 d, and TEMPOL and RNPO were 6 
administered daily, 1 h before IND administration. As shown in Figure 6, the daily 7 
administration of IND caused severe damage to the small intestines of mice, leading to a 8 
significant decrease in survival rate (28.6%) after 7 d treatment. However, the 9 
administration of LMW TEMPOL did not result in any improvement (14.3%), 10 
indicating the low efficiency of TEMPOL in reducing the IND-induced the intestinal 11 
inflammation. In contrast, the survival rate of mice treated daily with RNPO (57.1%) 12 
was remarkably increased. It is emphasized that the high accumulation and long 13 
retention of RNPO in the intestinal area are critical factors to reduce IND-induced small 14 
intestinal inflammation. 15 
 16 
4. Conclusions 17 
This study demonstrates the protective effect of orally administered RNPO on 18 
21 
 
IND-induced small intestinal inflammation in mice. Compared to LMW nitroxide 1 
radical compounds, RNPO showed remarkable accumulation and long retention in the 2 
jejunum and ileum, especially in the mucosa layer, resulting in effective scavenging of 3 
ROS and suppression of inflammation in the small intestines of IND-treated mice. On 4 
the basis of these results, we believe that the oral administration of RNPO, prior to the 5 
oral administration of NSAIDs, might become an important approach for the treatment 6 
of small intestinal injury in patients regularly taking NSAIDs. 7 
 8 
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 10 
Figure Legends 11 
Figure 1. Schematic illustration of RNPO and nanotherapeutics for the treatment of 12 
NSAID-induced small intestinal inflammation in mice. (a) RNPO is prepared by 13 
self-assembly of a methoxy-poly(ethylene 14 
glycol)-b-poly(4-[2,2,6,6-tetramethylpiperidine-1-oxyl]oxymethylstyrene) 15 
(MeO-PEG-b-PMOT) block copolymer possessing nitroxide radicals as side chains of 16 
hydrophobic segment. (b) After oral administration, RNPO accumulates in the mucosa 17 
of small intestine and scavenges ROS effectively. 18 
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 1 
Figure 2. Localization of RNPO in the ileum was determined with rhodamine-labeled 2 
RNPO. Mice were sacrificed 0.5, 1, 2, 4, and 12 h after the oral administration of 1 mL 3 
of rhodamine-labeled RNPO at a dose of 5 mg/mL (n = 3 mice per group), and ileum 4 
sections were cut circularly. The localization of rhodamine-labeled RNPO in the ileum 5 
was analyzed by fluorescent microscopy. Scale bars = 200 µm. Lu and Se in figure 6 
indicate lumen and serosa, respectively. 7 
 8 
Figure 3. (a) Accumulation of LMW TEMPOL (open circle) and RNPO (closed circle) 9 
in the jejunum. After the oral administration of LMW TEMPOL or RNPO with 10 
equivalent molar amount of nitroxide radicals (14.5 µmol), the amount of nitroxide 11 
radicals was measured using electron spin resonance (ESR). Data are expressed as mean 12 
± SEM. from 5 mice per group. (b) Accumulation of LMW TEMPOL (open circle) and 13 
RNPO (closed circle) in the ileum. Data are expressed as mean ± SEM. from 5 mice per 14 
group. (c) The ESR spectrum of LMW TEMPOL in the ileum homogenate at 0.5 h after 15 
oral administration. (d) The ESR spectrum of RNPO in the ileum homogenate at 0.5 h 16 
after oral administration. 17 
 18 
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Figure 4. Histological assessments by hematoxylin and eosin (H&E) staining. At 12 h 1 
after treatment, the jejunum and ileum were collected, and 7-µm-thick sections of 2 
jejunum and ileum were prepared. Sections of the jejunum and ileum were stained by 3 
H&E and assessed histologically. Red arrows indicate the lesion areas. Scale bars = 200 4 
µm. 5 
 6 
Figure 5. Protective effect of RNPO on IND-induced small intestinal inflammation in 7 
mice. At 12 h after treatment, jejunum (open bar) and ileum (closed bar) homogenates 8 
were prepared, and myeloperoxidase (MPO) activity, superoxide anion generation, and 9 
malondialdehyde (MDA) levels were measured. (a) MPO activity was determined by a 10 
colorimetric assay using o-dianisidine hydrochloride and H2O2 as substrates. (b) The 11 
generation of the superoxide anion was determined by the NBT assay. (c) Lipid 12 
peroxidation was measured by MDA formation in intestinal tissue homogenates. Data 13 
are expressed as mean ± SEM. #P < 0.05 vs. control, *P < 0.05 vs. IND, and ¶P < 0.05 14 
vs. TEMPOL from 5 mice per group. 15 
 16 
Figure 6. RNPO increased the survival rate of mice with IND-induced small intestinal 17 
inflammation. The survival rate of mice was determined following the oral 18 
28 
 
administration of IND (10 mg/kg BW) daily for 7 d. LMW TEMPOL (18.67 mg/kg 1 
BW) and RNPO (100 mg/kg BW) were orally administered 1 h before IND daily for 7 d, 2 
and the number of surviving mice was counted for 7 d. n = 7 mice per group. 3 
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